HARMONY 4: Randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

Diabetologia

Volumn 57, Issue 12, 2014, Pages 2475-2484

  Weissman, Peter N ^a   Carr, Molly C ^b   Ye, June ^b   Cirkel, Deborah T ^c   Stewart, Murray ^b   Perry, Caroline ^b   Pratley, Richard ^d  

^a Endocrinology Associates   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d FLORIDA HOSPITAL   (United States)

Author keywords

Albiglutide; GLP 1 agonist; Insulin glargine; Type 2 diabetes

Indexed keywords

ALBIGLUTIDE; HEMOGLOBIN A1C; INSULIN GLARGINE; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT; GLARGINE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; LONG ACTING INSULIN; RGLP-1 PROTEIN; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BODY WEIGHT; BRONCHITIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETIC PATIENT; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; INJECTION SITE BLEEDING; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INSULIN HYPOGLYCEMIA; INSULIN TREATMENT; INTERACTIVE VOICE RESPONSE SYSTEM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTPATIENT; PANCREATITIS; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; SKIN REDNESS; THYROID CANCER; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; RETREATMENT; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; METFORMIN; MIDDLE AGED; RETREATMENT; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919772916     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3360-3     Document Type: Article

References (28)

1. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 281:2005-2012
2. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364-1379
3. Dailey G, Admane K, Mercier F, Owens D (2010) Relationship of insulin dose, a1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Diabetes Technol Ther 12:1019-1027
4. Little S, Shaw J, Home P (2011) Hypoglycemia rates with basal insulin analogs. Diabetes Technol Ther 13(Suppl 1):S53-S64
5. Unger J (2012) Uncovering undetected hypoglycemic events. Diabetes Metab Syndr Obes 5:57-74
6. Russell-Jones D, Khan R (2007) Insulin-associated weight gain in diabetes: causes, effects and coping strategies. Diabetes Obes Metab 9:799-812
7. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705
8. Garber AJ (2011) Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 34(Suppl 2):S279-S284
9. Bush MA, Matthews JE, De Boever EH et al (2009) Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 11:498-505
10. Matthews JE, Stewart MW, De Boever EH et al (2008) Pharmacodynamics, pharmacokinetics, safety and tolerability of albiglutide, a long-acting GLP-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 93:4810-4817
11. AmericanDiabetes AssociationWorkgroup onHypoglycemia (2005) Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association. Diabetes Care 28:1245-1249
12. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG (2005) Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143:559-569
13. Russell-Jones D, Vaag A, Schmitz O et al (2009) Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 52:2046-2055
14. Seino Y, Inagaki N, Miyahara H et al (2014) A randomized dosefinding study demonstrating efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. Curr Med Res Opin 30:1095-1106
15. Philis-Tsimikas A (2013) Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize glycemic control. Am J Med 126:S21-S27
16. Novo Nordisk (April 2013) Victoza (liraglutide [rDNA origin] injection) [prescribing information]. Novo Nordisk, Princeton, NJ
17. Pratley RE, Nauck MA, Barnett AH et al (2014) Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol 2:289-297
18. Amylin Pharmaceuticals (January 2012) Bydureon (exenatide extended-release for injectable suspension) [prescribing information]. Amylin Pharmaceuticals, San Diego, CA
19. Buse JB, Nauck M, Forst T et al (2013) Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381:117-124
20. Drucker DJ, Buse JB, Taylor K et al (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 372:1240-1250
21. Blevins T, Pullman J, Malloy J et al (2011) DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 96:1301-1310
22. Chou E, Wang H, MiaoW, Germe M, FournierM, Schwartz S (2012) Adherence to GLP-1 agonist therapy in U.S. managed care. Diabetes 61(Suppl 1):A314
23. American Diabetes Association (2013) Standards of medical care in diabetes-2013. Diabetes Care 36(Suppl 1):S11-S66
24. Garber AJ, Abrahamson MJ, Barzilay JI et al (2013) AACE comprehensive diabetesmanagement algorithm 2013. Endocr Pract 19:327-336
25. Monami M, Dicembrini I, Marchionni N, Rotella CM, Mannucci E (2012) Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis. Exp Diabetes Res 2012:672-658
26. Heintjes EM, Thomsen TL, Penning-van Beest FJ, Christensen TE, Herings RM (2010) Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes. Adv Ther 27:211-222
27. Pratley R, Stewart M, Cirkel D, Ye J, Perry C, Carr MC (2013) HARMONY 4: 52-wk efficacy of albiglutide (Albi) vs. insulin glargine (Glar) in patients (pts) with T2DM. ADA, late breaking abstracts, available from http://professional.diabetes.org/admin/ UserFiles/combinedfile.pdf (Abstract 54-LB)
28. Pratley R, Stewart M, Cirkel D, Ye J, Perry C, Carr MC (2013) HARMONY 4: 52-week efficacy of albiglutide vs. insulin glargine in patients with type 2 diabetes mellitus. Diabetologia 56(Suppl): S360-S361 (Abstract 904)